Which has stronger valuation and earnings, GLSI or BCAX?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is GLSI or BCAX more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -941.15% -368.53% Bicara Therapeutics N/A -35.89% -33.78%

Which has higher valuation and earnings, GLSI or AVBP?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A

Is GLSI or AVBP more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -941.15% -368.53% ArriVent BioPharma N/A -48.98% -45.44%

Greenwich LifeSciences (GLSI) Competitors

$23.03 -0.72 (-3.03%)

Closing price 04:00 PM Eastern

Extended Trading

$22.98 -0.05 (-0.22%)

As of 07:42 PM Eastern

Compare

GLSI vs. HROW, IMCR, BCAX, AVBP, and ARDX

Should you buy Greenwich LifeSciences stock or one of its competitors? MarketBeat compares Greenwich LifeSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Greenwich LifeSciences include Harrow (HROW), Immunocore (IMCR), Bicara Therapeutics (BCAX), ArriVent BioPharma (AVBP), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry.

How does Greenwich LifeSciences compare to Harrow?

Greenwich LifeSciences (NASDAQ:GLSI) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Harrow has higher revenue and earnings than Greenwich LifeSciences. Harrow is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
Harrow	$272.30M	5.86	-$5.14M	-$0.41	N/A

Greenwich LifeSciences has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-941.15%	-368.53%
Harrow	-5.57%	19.59%	2.26%

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Greenwich LifeSciences has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Harrow has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

In the previous week, Harrow had 5 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 5 mentions for Harrow and 0 mentions for Greenwich LifeSciences. Harrow's average media sentiment score of 0.54 beat Greenwich LifeSciences' score of 0.00 indicating that Harrow is being referred to more favorably in the news media.

Company	Overall Sentiment
Greenwich LifeSciences	Neutral
Harrow	Positive

Greenwich LifeSciences currently has a consensus price target of $47.50, indicating a potential upside of 106.25%. Harrow has a consensus price target of $69.43, indicating a potential upside of 62.29%. Given Greenwich LifeSciences' higher probable upside, equities analysts plainly believe Greenwich LifeSciences is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Harrow beats Greenwich LifeSciences on 10 of the 15 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Greenwich LifeSciences has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

Immunocore currently has a consensus target price of $56.71, suggesting a potential upside of 94.23%. Greenwich LifeSciences has a consensus target price of $47.50, suggesting a potential upside of 106.25%. Given Greenwich LifeSciences' higher probable upside, analysts clearly believe Greenwich LifeSciences is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Immunocore had 2 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 2 mentions for Immunocore and 0 mentions for Greenwich LifeSciences. Immunocore's average media sentiment score of 1.15 beat Greenwich LifeSciences' score of 0.00 indicating that Immunocore is being referred to more favorably in the media.

Company	Overall Sentiment
Immunocore	Positive
Greenwich LifeSciences	Neutral

Immunocore has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

84.5% of Immunocore shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 10.1% of Immunocore shares are held by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Greenwich LifeSciences has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.71	-$35.51M	-$0.55	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

Summary

Immunocore beats Greenwich LifeSciences on 10 of the 16 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Bicara Therapeutics?

Greenwich LifeSciences (NASDAQ:GLSI) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

4.2% of Greenwich LifeSciences shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bicara Therapeutics' return on equity of -35.89% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-941.15%	-368.53%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Greenwich LifeSciences presently has a consensus target price of $47.50, suggesting a potential upside of 106.25%. Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 21.09%. Given Greenwich LifeSciences' higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, Greenwich LifeSciences' average media sentiment score of 0.00 equaled Bicara Therapeutics'average media sentiment score.

Company	Overall Sentiment
Greenwich LifeSciences	Neutral
Bicara Therapeutics	Neutral

Greenwich LifeSciences has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.53, indicating that its share price is 153% less volatile than the broader market.

Summary

Greenwich LifeSciences and Bicara Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Greenwich LifeSciences compare to ArriVent BioPharma?

Greenwich LifeSciences (NASDAQ:GLSI) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

In the previous week, ArriVent BioPharma had 2 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 2 mentions for ArriVent BioPharma and 0 mentions for Greenwich LifeSciences. ArriVent BioPharma's average media sentiment score of 0.32 beat Greenwich LifeSciences' score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Greenwich LifeSciences	Neutral
ArriVent BioPharma	Neutral

Greenwich LifeSciences presently has a consensus target price of $47.50, indicating a potential upside of 106.25%. ArriVent BioPharma has a consensus target price of $43.38, indicating a potential upside of 28.56%. Given Greenwich LifeSciences' higher possible upside, equities analysts clearly believe Greenwich LifeSciences is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Greenwich LifeSciences has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ArriVent BioPharma's return on equity of -48.98% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-941.15%	-368.53%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Summary

ArriVent BioPharma beats Greenwich LifeSciences on 10 of the 14 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Ardelyx?

Greenwich LifeSciences (NASDAQ:GLSI) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, Ardelyx had 2 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 2 mentions for Ardelyx and 0 mentions for Greenwich LifeSciences. Ardelyx's average media sentiment score of 0.67 beat Greenwich LifeSciences' score of 0.00 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Overall Sentiment
Greenwich LifeSciences	Neutral
Ardelyx	Positive

Greenwich LifeSciences has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-941.15%	-368.53%
Ardelyx	-13.58%	-38.11%	-11.85%

Greenwich LifeSciences presently has a consensus price target of $47.50, indicating a potential upside of 106.25%. Ardelyx has a consensus price target of $15.73, indicating a potential upside of 154.49%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Greenwich LifeSciences has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
Ardelyx	$407.32M	3.75	-$61.60M	-$0.23	N/A

Greenwich LifeSciences has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 5.3% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Ardelyx beats Greenwich LifeSciences on 11 of the 16 factors compared between the two stocks.

Get Greenwich LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLSI vs. The Competition

Export

Metric	Greenwich LifeSciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$348.61M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-14.67	19.75	24.92	23.98
Price / Sales	N/A	330.11	529.01	109.54
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	767.67	8.29	10.79	6.50
Net Income	-$19.36M	$23.85M	$3.56B	$336.88M
7 Day Performance	-3.56%	5.21%	1.67%	-0.22%
1 Month Performance	-16.71%	2.19%	0.43%	0.77%
1 Year Performance	162.90%	60.99%	32.84%	31.57%

Greenwich LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLSI Greenwich LifeSciences	1.2239 of 5 stars	$23.03 -3.0%	$47.50 +106.3%	+166.9%	$348.61M	N/A	N/A	3	Positive News
HROW Harrow	4.3177 of 5 stars	$38.40 -1.4%	$69.43 +80.8%	+38.3%	$1.43B	$272.30M	N/A	180	News Coverage
IMCR Immunocore	3.3779 of 5 stars	$27.98 -2.3%	$56.71 +102.7%	-6.3%	$1.42B	$400.02M	N/A	320	News Coverage Positive News
BCAX Bicara Therapeutics	1.6272 of 5 stars	$21.54 -0.1%	$30.27 +40.5%	+163.4%	$1.42B	N/A	N/A	32
AVBP ArriVent BioPharma	2.2389 of 5 stars	$29.77 -1.8%	$43.38 +45.7%	+29.7%	$1.39B	N/A	N/A	40	News Coverage Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLSI) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Greenwich LifeSciences (GLSI) Competitors

GLSI vs. HROW, IMCR, BCAX, AVBP, and ARDX

How does Greenwich LifeSciences compare to Harrow?

Summary

How does Greenwich LifeSciences compare to Immunocore?

Summary

How does Greenwich LifeSciences compare to Bicara Therapeutics?

Summary

How does Greenwich LifeSciences compare to ArriVent BioPharma?

Summary

How does Greenwich LifeSciences compare to Ardelyx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI vs. The Competition

Greenwich LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Greenwich LifeSciences (GLSI) Competitors

GLSI vs. HROW, IMCR, BCAX, AVBP, and ARDX

How does Greenwich LifeSciences compare to Harrow?

Which has higher valuation and earnings, GLSI or HROW?

Is GLSI or HROW more profitable?

Do insiders & institutionals have more ownership in GLSI or HROW?

Which has more volatility and risk, GLSI or HROW?

Does the media favor GLSI or HROW?

Do analysts recommend GLSI or HROW?

Summary

How does Greenwich LifeSciences compare to Immunocore?

Is IMCR or GLSI more profitable?

Do analysts rate IMCR or GLSI?

Does the media refer more to IMCR or GLSI?

Which has more volatility & risk, IMCR or GLSI?

Do insiders & institutionals have more ownership in IMCR or GLSI?

Which has preferable earnings & valuation, IMCR or GLSI?

Summary

How does Greenwich LifeSciences compare to Bicara Therapeutics?

Which has stronger valuation and earnings, GLSI or BCAX?

Do insiders and institutionals hold more shares of GLSI or BCAX?

Is GLSI or BCAX more profitable?

Do analysts prefer GLSI or BCAX?

Does the media favor GLSI or BCAX?

Which has more risk & volatility, GLSI or BCAX?

Summary

How does Greenwich LifeSciences compare to ArriVent BioPharma?

Does the media favor GLSI or AVBP?

Do analysts prefer GLSI or AVBP?

Which has higher valuation and earnings, GLSI or AVBP?

Which has more risk and volatility, GLSI or AVBP?

Do institutionals and insiders believe in GLSI or AVBP?

Is GLSI or AVBP more profitable?

Summary

How does Greenwich LifeSciences compare to Ardelyx?

Does the media favor GLSI or ARDX?

Is GLSI or ARDX more profitable?

Do analysts rate GLSI or ARDX?

Which has preferable earnings and valuation, GLSI or ARDX?

Which has more risk and volatility, GLSI or ARDX?

Do insiders and institutionals believe in GLSI or ARDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI vs. The Competition

Greenwich LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools